Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus plantarum LP01

What does the research say about Lactobacillus plantarum LP01?

2 health outcomes synthesised

Lactobacillus plantarum LP01 has been studied across 2 health outcomes, primarily focusing on gastrointestinal health. The strongest evidence is for reduced gastrointestinal symptoms, based on 3 studies showing moderate effects in patients undergoing digestive surgery or bowel preparation. The most commonly studied dose is 1 billion CFU/day, though nearly all research used multi-strain formulations, making it difficult to isolate the effects of LP01 alone.

Strongest evidence

The available research on Lactobacillus plantarum LP01 is limited in scope and strength. Both synthesized outcomes — reduced gastrointestinal symptoms and improved stool formation — are supported by 3 studies each and are rated as having low evidence strength. In both cases, all 3 studies reported beneficial effects of moderate size. For gastrointestinal symptoms, the populations studied were patients undergoing digestive surgery or bowel preparation. For stool formation, the populations included outpatients undergoing digestive surgery, those with chronic intestinal disorders, and those undergoing bowel preparation. The effective dose identified in one study for each outcome was 1 billion CFU/day.

Mixed or weaker evidence

There are no outcomes with high or moderate evidence strength for this probiotic. Both outcomes are classified as low evidence, meaning conclusions should be considered preliminary. No studies reported harmful or neutral results, but the small number of studies and potential publication bias (null results are less likely to be published) are significant limitations.

Effective dose patterns

The only effective dose reported across the studies is 1 billion living cells/day, appearing in both syntheses. However, this dose was always administered as part of a multi-strain product (primarily Abincol®), so the optimal dose for LP01 alone cannot be determined from this evidence.

Population insights

The research primarily focused on outpatient populations with digestive surgery, bowel preparation, or chronic intestinal disorders. No cross-cutting insights for other populations (e.g., healthy adults, elderly, children) are available due to the narrow scope of the studies.

Notable caveats

  • Small evidence base: Only 3 studies per outcome, making all findings preliminary.
  • Multi-strain formulations: All studies used multi-strain products, so the specific contribution of Lactobacillus plantarum LP01 cannot be isolated.
  • Publication bias: The available evidence is overwhelmingly positive, but clinical literature in this area is subject to publication bias — null-result studies are less likely to be published.

Frequently asked

  • What is Lactobacillus plantarum LP01 good for according to research?
    Research on Lactobacillus plantarum LP01 (almost always in combination with other strains) has examined two health outcomes: reducing gastrointestinal symptoms and improving stool formation. In both areas, 3 studies reported moderate beneficial effects in patients undergoing digestive surgery, bowel preparation, or with chronic intestinal disorders. However, the evidence is rated low in strength.
  • What dose of Lactobacillus plantarum LP01 is typically used in studies?
    The most studied dose is 1 billion CFU (living cells) per day. This dose was used in one study for each outcome, always as part of a multi-strain probiotic mixture. No high-quality dose-ranging studies are available.
  • Who benefits most from Lactobacillus plantarum LP01 according to the research?
    The populations studied were patients undergoing digestive surgery, those preparing for bowel procedures, and outpatients with chronic intestinal disorders. Because all studies used multi-strain products and the evidence base is small, it is unclear how well these findings apply to healthy adults or other groups.
  • Are there caveats or limitations in the research on Lactobacillus plantarum LP01?
    Yes. The evidence base is small (only 3 studies per outcome), and all studies tested multi-strain formulations, making it impossible to attribute effects solely to LP01. Additionally, the available evidence is overwhelmingly positive, which may reflect publication bias — null results are less likely to be published or indexed. Conclusions should be considered preliminary.
  • Does Lactobacillus plantarum LP01 help with improving stool formation?
    Three studies reported moderate beneficial effects of a multi-strain product containing Lactobacillus plantarum LP01 on improved stool formation in outpatients undergoing digestive surgery, bowel preparation, or those with chronic intestinal disorders. The evidence strength is low, and the specific contribution of LP01 alone cannot be isolated.

Most-studied combinations with Lactobacillus plantarum LP01

most supplement research is combination research
Also studied with:Lactobacillus rhamnosus LR06 (2), Lactobacillus paracasei LPC09 (2), Bifidobacterium plantarum (2)

  • Women's Probiotic

    By MRM Nutrition

    4.6 (5.7K reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $15.38
    		In
    Vitacost
    $15.38
    		In
    Vitamin Shoppe
    $-
    		Out

  • All-Flora Probiotic

    By New Chapter

    4.7 (84 reviews)
    In Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $54.97
    		In
    Vitacost
    $54.97
    		In
    Vitamin Shoppe
    $-
    		Out

  • All-Flora Probiotic

    By New Chapter

    4.7 (87 reviews)
    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $29.97
    		In
    Vitacost
    $29.97
    		In
    Vitamin Shoppe
    $32.86
    		In
Back to top